CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 119 enrolled
Drug / intervention
Solumedrol +1 moredrug
Likely dose
Solumedrol 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00807586
NCT00807586Phase 4Completed
CompareCT.gov

SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation

Minneapolis Heart Institute Foundation·interventional·Posted Dec 12, 2008·Updated Aug 20, 2019

In Brief

A Phase 4 clinical trial evaluating Solumedrol and Placebo for Atrial Fibrillation. Completed, enrolled 119 participants across 1 site.

Detailed Summary

Radiofrequency ablation is an effective treatment for atrial fibrillation. However, about 20% of the time the atrial fibrillation recurs. Steroids given after the ablation may decrease inflammation caused by the ablation and thus improve healing and decrease the chance of recurrence of atrial fibrillation. In this study patients will be randomized to receive intravenous steroids or not immediately following the ablation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
CollaboratorsAbbott Medical Devices

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 12, 2008
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2009
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.6 years ago

Interventions

Solumedroldrug

100mg, given once within 2 hours of the end of the ablation procedure

Placebodrug

Normal saline (1.6 cc)